Literature DB >> 32755665

Cardiogenic shock and cardiac arrest complicating ST-segment elevation myocardial infarction in the United States, 2000-2017.

Saraschandra Vallabhajosyula1, Shannon M Dunlay2, Abhiram Prasad3, Lindsey R Sangaralingham4, Kianoush Kashani5, Nilay D Shah6, Jacob C Jentzer7.   

Abstract

BACKGROUND: There are limited data on the outcomes of cardiogenic shock (CS) and cardiac arrest (CA) complicating ST-segment-elevation myocardial infarction (STEMI).
METHODS: Adult (>18 years) STEMI admissions were identified using the National Inpatient Sample (2000-2017) and classified as CS + CA, CS only, CA only and no CS/CA. Outcomes of interest included temporal trends, in-hospital mortality, hospitalization costs, use of do-not-resuscitate (DNR) status and palliative care referrals across the four cohorts.
RESULTS: Of the 4,320,117 STEMI admissions, CS, CA and both were noted in 5.8%, 6.2% and 2.7%, respectively. In 2017, compared to 2000, there was an increase in CA (adjusted odds ratio [aOR] 1.83 [95% confidence interval {CI} 1.79-1.86]), CS (aOR 3.92 [95% CI 3.84-4.01]) and both (aOR 4.09 [95% CI 3.94-4.24]) (all p < 0.001). The CS+CA (77.2%) cohort had higher rates of multiorgan failure than CS only (59.7%) and CA only (26.3%), p < 0.001. The CA only cohort had lower rates (64%) of coronary angiography compared to the other groups (>70%), p < 0.001. In-hospital mortality was higher in CS+CA compared to CS alone (adjusted OR 1.87 [95% CI 1.83-1.91]), CA alone (adjusted OR 1.99 [95% CI 1.95-2.03]) or neither (aOR 18.37 [95% CI 18.02-18.71]). The CS+CA cohort had higher use of palliative care and DNR status. The presence of CS, either alone or in combination with CA, was associated with higher hospitalization costs.
CONCLUSIONS: The combination of CS and CA was associated with higher rates of non-cardiac organ failure and in-hospital mortality in STEMI compared to those with either CS or CA alone.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute cardiovascular care; Cardiac arrest; Cardiogenic shock; Outcomes research; ST-segment elevation myocardial infarction

Mesh:

Year:  2020        PMID: 32755665     DOI: 10.1016/j.resuscitation.2020.07.022

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  6 in total

Review 1.  Impella to Treat Acute Myocardial Infarct-Related Cardiogenic Shock.

Authors:  Jacob Eifer Møller; Jesper Kjaergaard; Christian Juhl Terkelsen; Christian Hassager
Journal:  J Clin Med       Date:  2022-04-26       Impact factor: 4.964

2.  Epidemiology of cardiogenic shock and cardiac arrest complicating non-ST-segment elevation myocardial infarction: 18-year US study.

Authors:  Saraschandra Vallabhajosyula; Jacob C Jentzer; Abhiram Prasad; Lindsey R Sangaralingham; Kianoush Kashani; Nilay D Shah; Shannon M Dunlay
Journal:  ESC Heart Fail       Date:  2021-04-09

3.  Concomitant Sepsis Diagnoses in Acute Myocardial Infarction-Cardiogenic Shock: 15-Year National Temporal Trends, Management, and Outcomes.

Authors:  Jacob C Jentzer; Anusha G Bhat; Sri Harsha Patlolla; Shashank S Sinha; P Elliott Miller; Patrick R Lawler; Sean van Diepen; Ashish K Khanna; David X Zhao; Saraschandra Vallabhajosyula
Journal:  Crit Care Explor       Date:  2022-02-04

4.  Commentary: A Review of Prognosis Model Associated With Cardiogenic Shock After Acute Myocardial Infarction.

Authors:  Oriol Iborra-Egea; Cosme García-García; Antoni Bayés-Genís
Journal:  Front Cardiovasc Med       Date:  2022-02-23

Review 5.  A Clinical Update on Vasoactive Medication in the Management of Cardiogenic Shock.

Authors:  Aditi Shankar; Gayathri Gurumurthy; Lakshmi Sridharan; Divya Gupta; William J Nicholson; Wissam A Jaber; Saraschandra Vallabhajosyula
Journal:  Clin Med Insights Cardiol       Date:  2022-02-07

6.  Intra-Aortic Balloon Pump for Left Ventricular Unloading in Veno-Arterial Extracorporeal Membrane Oxygenation: The Last Remaining Indication in Cardiogenic Shock.

Authors:  Agam Bansal; Dhiran Verghese; Saraschandra Vallabhajosyula
Journal:  J Am Heart Assoc       Date:  2022-04-04       Impact factor: 6.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.